FDA Grants RMAT Designation to Avobis Bio's Implantable Cell Therapy AVB-114 for Crohn's Perianal Fistulas

Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that the U.S. Food and Drug ...

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...
InvestorsHub on MSN

Spruce Biosciences Shares Surge After FDA Grants Breakthrough Therapy Designation

Shares of Spruce Biosciences (NASDAQ:SPRB) jumped 60% on Monday after the company announced that the U.S. Food and Drug ...
Pharmabiz

Avobis Bio's implantable cell therapy, AVB-114 for Crohn's perianal fistulas receives US FDA RMAT designation

Avobis Bio's implantable cell therapy, AVB-114 for Crohn's perianal fistulas receives US FDA RMAT designation: Newark, Delaware Monday, October 6, 2025, 12:00 Hrs [IST] Avobis Bio ...